Nebivolol Teva

Nebivolol, the active ingredient in Nebivolol Teva, is a selective β1‑adrenergic receptor blocker presented as a tablet for oral administration. It is used to lower elevated blood pressure in adult patients, helping to reduce the risk of cardiovascular complications associated with hypertension. The medication works by slowing heart rate and promoting nitric‑oxide‑mediated vasodilation, contributing to improved blood pressure control.

GNH USA supplies Nebivolol Teva as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Nebivolol is indicated for the management of hypertension, a condition characterized by elevated arterial pressure. - Hypertension (essential): lowers systolic and diastolic blood pressure in adult patients. - High blood pressure (stage 1 or 2): provides sustained blood pressure control when lifestyle measures are insufficient. - Blood pressure management in cardiovascular risk reduction: contributes to decreased risk of stroke and myocardial infarction in hypertensive individuals.

Nebivolol may be associated with several adverse reactions, ranging from mild to serious.

Common Side Effects: - Headache: mild to moderate intensity. - Dizziness or light‑headedness: especially on standing. - Fatigue or tiredness: general lack of energy. - Nausea: occasional gastrointestinal upset. - Bradycardia: slower than normal heart rate. - Peripheral edema: mild swelling of ankles or feet.

Serious or Rare Side Effects: - Severe bradycardia: markedly low heart rate requiring medical attention. - Atrioventricular block: impaired electrical conduction of the heart. - Hypotension: significant drop in blood pressure causing faintness. - Allergic reactions: rash, itching, or swelling of face and throat. - Liver injury: elevated liver enzymes or hepatitis.

When prescribing Nebivolol, clinicians should consider several precautionary measures to ensure safe use. - Blood pressure monitoring: check baseline and regularly assess response. - Heart rate assessment: avoid use in patients with resting bradycardia (<50 bpm). - Liver function: use caution in moderate to severe hepatic impairment. - Drug discontinuation: do not stop abruptly; taper under medical supervision. - Contraindications: avoid in patients with second‑ or third‑degree AV block. - Store at room temperature: keep in the original container, protect from moisture and direct sunlight.

Nebivolol can interact with other medicines, affecting its efficacy or safety.

Major Interactions (Avoid): - Other beta‑blockers: additive bradycardia and hypotension. - Potent CYP2D6 inhibitors (e.g., paroxetine, quinidine): increase nebivolol plasma levels. - Calcium‑channel blockers that depress conduction (e.g., verapamil, diltiazem): may cause excessive heart rate slowing. - Antiarrhythmic agents (e.g., amiodarone): heightened risk of AV block.

Moderate Interactions (Monitor Closely): - ACE inhibitors or ARBs: may enhance antihypertensive effect, monitor blood pressure. - Diuretics: combined effect on blood pressure, watch for orthostatic hypotension. - NSAIDs: may reduce antihypertensive efficacy, assess renal function. - Antidiabetic drugs: beta‑blockade may mask hypoglycemia symptoms, monitor glucose.